

Jordi Mancebo, M.D.\*  
 Servei Medicina Intensiva  
 Hospital Universitari Sant Pau  
 Barcelona, Spain

\*J.M. is Associate Editor of *AJRCCM*. His participation complies with American Thoracic Society requirements for recusal from review and decisions for authored works.

## References

- Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, *et al.*; LUNG SAFE Investigators; ESICM Trials Group. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. *JAMA* 2016;315:788–800.
- Fan E, Del Sorbo L, Goligher EC, Hodgson CL, Munshi L, Walkey AJ, *et al.*; American Thoracic Society, European Society of Intensive Care Medicine, and Society of Critical Care Medicine. An official American thoracic society/European society of intensive care medicine/society of critical care medicine clinical practice guideline: mechanical ventilation in adult patients with acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2017;195:1253–1263.
- Papazian L, Aubron C, Brochard L, Chiche JD, Combes A, Dreyfuss D, *et al.* Formal guidelines: management of acute respiratory distress syndrome. *Ann Intensive Care* 2019;9:69.
- Guérin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, *et al.*; PROSEVA Study Group. Prone positioning in severe acute respiratory distress syndrome. *N Engl J Med* 2013;368:2159–2168.
- Sud S, Friedrich JO, Adhikari NK, Taccone P, Mancebo J, Polli F, *et al.* Effect of prone positioning during mechanical ventilation on mortality among patients with acute respiratory distress syndrome: a systematic review and meta-analysis. *CMAJ* 2014;186:E381–E390.
- Munshi L, Del Sorbo L, Adhikari NKJ, Hodgson CL, Wunsch H, Meade MO, *et al.* Prone position for acute respiratory distress syndrome: a systematic review and meta-analysis. *Ann Am Thorac Soc* 2017;14:S280–S288.
- Guérin C, Beuret P, Constantin JM, Bellani G, Garcia-Olivares P, Roca O, *et al.*; investigators of the APRONET Study Group, the REVA Network, the Réseau recherche de la Société Française d'Anesthésie-Réanimation (SFAR-recherche) and the ESICM Trials Group. A prospective international observational prevalence study on prone positioning of ARDS patients: the APRONET (ARDS Prone Position Network) study. *Intensive Care Med* 2018;44:22–37.
- Sud S, Friedrich JO, Adhikari NKJ, Fan E, Ferguson ND, Guyatt G, *et al.* Comparative effectiveness of protective ventilation strategies for moderate and severe acute respiratory distress syndrome: a network meta-analysis. *Am J Respir Crit Care Med* 2021;203:1366–1377.
- Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A; Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 2000;342:1301–1308.
- Fan E, Beitler JR, Brochard L, Calfee CS, Ferguson ND, Slutsky AS, *et al.* COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted? *Lancet Respir Med* 2020;8:816–821.
- Ferrando C, Suarez-Sipmann F, Mellado-Artigas R, Hernández M, Gea A, Arruti E, *et al.*; COVID-19 Spanish ICU Network. Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS. *Intensive Care Med* 2020;46:2200–2211. [Published erratum appears in *Intensive Care Med* 47:144–146.]
- Gattinoni L, Camporota L, Marini JJ. COVID-19 phenotypes: leading or misleading? *Eur Respir J* 2020;56:2002195.
- Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, *et al.* COVID-19 pneumonia: different respiratory treatments for different phenotypes? *Intensive Care Med* 2020;46:1099–1102.
- Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. COVID-19 does not lead to a “typical” acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2020;201:1299–1300.
- Grieco DL, Bongiovanni F, Chen L, Menga LS, Cutuli SL, Pintaudi G, *et al.* Respiratory physiology of COVID-19-induced respiratory failure compared to ARDS of other etiologies. *Crit Care* 2020;24:529.
- Panwar R, Madotto F, Laffey JG, van Haren FMP. Compliance phenotypes in early acute respiratory distress syndrome before the COVID-19 pandemic. *Am J Respir Crit Care Med* 2020;202:1244–1252.
- COVID-ICU group on behalf of the REVA Network and the COVID-ICU Investigators. Clinical Characteristics and Day-90 Outcomes of 4,244 critically ill adults with COVID-19: a prospective cohort study. *Intensive Care Med* 2020;47:60–73.
- Amato MB, Meade MO, Slutsky AS, Brochard L, Costa EL, Schoenfeld DA, *et al.* Driving pressure and survival in the acute respiratory distress syndrome. *N Engl J Med* 2015;372:747–755.
- Goligher EC, Costa ELV, Yarnell CJ, Brochard LJ, Stewart TE, Tomlinson G, *et al.* Effect of lowering tidal volume on mortality in ARDS varies with respiratory system elastance. *Am J Respir Crit Care Med* [online ahead of print] 13 Jan 2021; DOI: 10.1164/rccm.202009-3536OC.
- Beitler JR, Sarge T, Banner-Goodspeed VM, Gong MN, Cook D, Novack V, *et al.*; EPVent-2 Study Group. Effect of titrating Positive End-Expiratory Pressure (PEEP) with an esophageal pressure-guided strategy vs an empirical high PEEP-Fio2 strategy on death and days free from mechanical ventilation among patients with acute respiratory distress syndrome: a randomized clinical trial. *JAMA* 2019;321:846–857.

Copyright © 2021 by the American Thoracic Society



## Do More Injured Lungs Need More Protection? Let's Test It

Driving pressure, calculated as the difference between plateau pressure and positive end-expiratory pressure (PEEP) during mechanical ventilation in a relaxed subject, has an independent association with the risk of death in patients with acute respiratory distress syndrome (ARDS) (1, 2), suggesting that interventions in these patients such as PEEP titration are beneficial only if associated with a decrease in driving

pressure. Lung computed tomography demonstrating heterogenous aeration in ARDS typically reveals dependent nonaerated lung, which is central to both our current understanding of ventilation strategies (3) and the typical increase in respiratory system stiffness (static elastance) estimated as the driving pressure divided by the  $V_T$ . Perhaps readers will be more familiar with compliance (the inverse of elastance); both static respiratory system elastance and compliance are largely influenced by the volume of aerated lung. As both the stress and strain resulting in ventilation-induced lung injury reflect  $V_T$  and end-expiratory lung volume, targeting driving pressure makes sense, as driving pressure, in effect, scales  $V_T$  to the magnitude of the reduced lung volume for a given patient with ARDS.

In this issue of the *Journal*, Goligher and colleagues (pp. 1378–1385) now provide supporting data, with a secondary

†This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (<https://creativecommons.org/licenses/by-nc-nd/4.0/>). For commercial usage and reprints, please contact Diane Gern (dgern@thoracic.org).

Originally Published in Press as DOI: 10.1164/rccm.202101-0154ED on February 9, 2021

analysis from five randomized trials, demonstrating a significant interaction of elastance and the effect of randomized  $V_T$  on mortality (4). With the use of Bayesian multivariable logistic regression and long-term (60-d mortality) as the primary outcome, patients with higher elastance (and hence higher driving pressures) are likely to accrue a greater mortality benefit with lower  $V_T$  compared with patients with lower elastance (and hence lower driving pressures), who are likely to accrue less mortality benefit. A Subpopulation Treatment Effect Pattern Plot analysis confirmed heterogeneity of the  $V_T$  treatment effect. Although their analysis provides credence that lung-protective ventilation strategies, and perhaps PEEP selection, should primarily target driving pressure, several considerations are required to reconcile this with earlier studies.

Lower  $V_T$  appears beneficial in both healthy and injured lungs. In the pivotal ARDS Network study examining lower versus higher  $V_T$  ventilation (5), the interaction between the randomized  $V_T$ s and the quartile of static compliance at baseline was not significant. Further analysis by Hager and colleagues of the ARDS Network data confirmed the lack of interaction and concluded that the benefit of lower  $V_T$  ventilation strategy was not associated with plateau pressure (6), suggesting that lower  $V_T$  was beneficial even when plateau pressure was low (and by extension, there was benefit when the elastance was also low). Analyzing a larger cohort than Hager and colleagues, Goligher and colleagues' analysis failed to find this relationship, perhaps because of the larger sample size and more sensitive analytic approaches. The elastance-dependent effect of  $V_T$  reduction is consistent with the observation in models of ventilation-induced lung injury, in which damage is exacerbated by the degree of preexisting lung dysfunction (7). Taken together, this suggests the maximum benefit of lowering  $V_T$  is found in the most severely injured lungs.

Goligher and colleagues and Amato and colleagues used Day 1 postrandomization respiratory system elastance and driving pressure values, respectively; ideally prerandomization elastance would be used, but these values are not available for many patients in this database. This is important, as ventilation with either higher or lower  $V_T$  could alter the post-treatment elastance. For example, randomization to higher  $V_T$  overnight could result in either tidal recruitment (and reduced elastance) or early ventilator-induced lung injury (and increased elastance) and introduce bias. Moreover, respiratory system elastance in patients with ARDS is not static; it changes over time, perhaps suggesting that a prospective study examining this concept would also need to be dynamic, reflecting regular assessments of elastance.

Respiratory system elastance is composed of both lung and chest wall compliance, making it a poor surrogate for transpulmonary pressure. Multiple factors such as increased body weight, chest wall deformity, markedly positive cumulative fluid balance, and raised intraabdominal pressure, among others, can all affect the chest wall elastance and, consequently, the respiratory system elastance. The respiratory system elastance was adjusted either to the predicted or the actual body weight based on data availability in the five examined studies, but as discussed by Goligher and colleagues, the driving pressure may need to be reconsidered when chest wall elastance is abnormally elevated.

The association presented in the present article, and multiple sensitivity analyses to address some of these concerns, provide some

compelling data, but design and implementation of high-quality prospective randomized clinical trials testing these findings to better inform management will be difficult. Theoretical analysis of mechanical power applied during ventilation (8), another newer approach to understanding ventilator-induced lung injury, groups driving pressure and  $V_T$  together, suggesting that it will be hard to separate the two during a clinical study. Furthermore, higher inspiratory flow rates increase mechanical power transmission, adding additional complexity to clinical trials of optimal lung protective ventilation. A contemporary usual care arm will include lower  $V_T$  ventilation and PEEP titration, noting that today's patients are more likely to also receive prone ventilation and restrictive fluid therapy. Early appropriate antibiotics, resuscitation and mobilization, reduced transfusion-related lung injury, and early corticosteroids (9) in appropriate patients with ARDS are among many other practice changes that reduce lung damage and improve outcomes, requiring even larger clinical trial enrollment to achieve adequate power.

The current analysis suggests that elastance (and thus driving pressure) predicts the effect of treatment with lower  $V_T$  and provides additional support for targeting an upper limit for driving pressure of 15 cm  $H_2O$ . Prospective testing of such a strategy could also stratify patients based on their respiratory system elastance; those with a high elastance could then be randomized to an ultra-low  $V_T$  strategy to decrease driving pressure further, possibly coupled with the use of extra corporeal carbon dioxide removal. Similarly, patients with low elastance could be randomized to higher  $V_T$ s that may be better tolerated. Until such studies are complete, the simplicity of repeated titration based on driving pressure is an attractive personalized approach as we strive to further improve outcomes from ARDS. ■

---

**Author disclosures** are available with the text of this article at [www.atsjournals.org](http://www.atsjournals.org).

Shailesh Bihari, M.B. B.S., M.D., Ph.D.  
*Department of Intensive Care Medicine  
 Flinders Medical Centre  
 South Australia, Australia*

and

*College of Medicine and Public Health  
 Flinders University  
 South Australia, Australia*

B. Taylor Thompson, M.D.\*  
*Division of Pulmonary and Critical Care Medicine  
 Massachusetts General Hospital  
 Boston, Massachusetts*

Andrew D. Bersten, M.B. B.S., M.D.  
*Department of Intensive Care Medicine  
 Flinders Medical Centre  
 South Australia, Australia*

and

*College of Medicine and Public Health  
 Flinders University  
 South Australia, Australia*

\*B.T.T. is Associate Editor of *AJRCCM*. His participation complies with American Thoracic Society requirements for recusal from review and decisions for authored works.

---

## References

- Amato MB, Meade MO, Slutsky AS, Brochard L, Costa EL, Schoenfeld DA, *et al*. Driving pressure and survival in the acute respiratory distress syndrome. *N Engl J Med* 2015;372:747–755.
- Urner M, Jüni P, Hansen B, Wettstein MS, Ferguson ND, Fan E. Time-varying intensity of mechanical ventilation and mortality in patients with acute respiratory failure: a registry-based, prospective cohort study. *Lancet Respir Med* 2020;8:905–913.
- Puybasset L, Cluzel P, Gusman P, Grenier P, Preteux F, Rouby JJ; CT Scan ARDS Study Group. Regional distribution of gas and tissue in acute respiratory distress syndrome: I. Consequences for lung morphology. *Intensive Care Med* 2000;26:857–869.
- Goligher EC, Costa ELV, Yamell CJ, Brochard LJ, Stewart TE, Tomlinson G, *et al*. Effect of lowering  $V_T$  on mortality in acute respiratory distress syndrome varies with respiratory system elastance. *Am J Respir Crit Care Med* 2021;203:1378–1385.
- Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A; Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 2000;342:1301–1308.
- Hager DN, Krishnan JA, Hayden DL, Brower RG; ARDS Clinical Trials Network. Tidal volume reduction in patients with acute lung injury when plateau pressures are not high. *Am J Respir Crit Care Med* 2005;172:1241–1245.
- Dreyfuss D, Saumon G. Ventilator-induced lung injury: lessons from experimental studies. *Am J Respir Crit Care Med* 1998;157:294–323.
- Gattinoni L, Tonetti T, Cressoni M, Cadringher P, Herrmann P, Moerer O, *et al*. Ventilator-related causes of lung injury: the mechanical power. *Intensive Care Med* 2016;42:1567–1575.
- Villar J, Ferrando C, Martínez D, Ambrós A, Muñoz T, Soler JA, *et al*.; dexamethasone in ARDS network. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. *Lancet Respir Med* 2020;8:267–276.

Copyright © 2021 by the American Thoracic Society



## ⊕ The Conundrum of Cleaner Cookstove Interventions: Necessary but Insufficient?

Forty percent of the world's population, nearly 3 billion people, rely on biomass fuels for daily cooking and energy needs. Incomplete combustion of biomass fuels results in high exposures to household air pollution (HAP), a complex and toxic mixture. The most commonly measured pollutants include fine particulate matter ( $PM_{2.5}$ ) and carbon monoxide (CO). In 2019, HAP was responsible for 2.3 million deaths and 91.5 million disability-adjusted life years (1). Together, cardiovascular disease and chronic respiratory diseases account for approximately 63% of all HAP-attributable deaths and 40% of disability-adjusted life years. Much of the burden is concentrated in low- and middle-income countries where, on average, an estimated 65% of households cook with solid fuels (2).

Despite this extraordinary burden of disease, randomized controlled trial (RCT) evidence supporting cleaner cookstove interventions to improve adult cardiopulmonary outcomes is lacking. Romieu and colleagues in 2009, and Hanna and colleagues in 2016, reported household-level chimney stove interventions versus traditional open-fire stoves, and intention-to-treat analyses found no effect on lung function decline, likely driven by low intervention uptake (3, 4). A report by Guarneri and colleagues in 2015 similarly found no evidence that a household-level chimney stove intervention improved adult lung function, but separately published exposure-response analyses were suggestive of an effect (5, 6). Zhou

and colleagues did conversely find that improved ventilation or biogas stoves for 9 years improved  $FEV_1$  decline as compared with open fire, suggesting that a long duration of follow up may be required to see health effects (7). Although broader prospective cohorts, including work from our group, generally show a positive association between HAP exposure and blood pressure (BP) and, over the life course, cardiovascular mortality, data from RCTs is limited (8–10). For example, a secondary analysis of an ethanol intervention and a pre-/postimproved cookstove study suggests that interventions to reduce HAP exposure may improve diastolic or systolic BP, respectively (11, 12). Given these mixed results, the global health community continues to seek evidence in support of a cookstove intervention strategy to improve health.

In this issue of the *Journal*, Checkley and colleagues (pp. 1386–1397) examine the effect of a year-long, multifaceted liquefied petroleum gas (LPG) cookstove intervention as compared with biomass (commonly animal dung) cookstove on cardiopulmonary health in adults, specifically resting BP, peak expiratory flow (PEF), and respiratory symptoms as measured by the St. George's Respiratory Questionnaire (13). The intervention included provision of a three-burner LPG stove, education and behavioral messaging, and biweekly LPG fuel refills and stove inspections and repairs for the duration of the study. Repeated personal exposures to  $PM_{2.5}$ , black carbon, and CO exposures as well as kitchen area  $PM_{2.5}$ , CO, and, in a subset, nitrogen dioxide ( $NO_2$ ) were measured. To understand patterns of stove use, temperature loggers were placed on LPG and biomass stoves in intervention homes and biomass stoves in control homes; 24 control homes also had temperature loggers placed on LPG stoves (71% of control households already owned an LPG stove). The authors are to be commended on the strength of their intervention, exposure measurement strategy, and objective health outcome assessments.

The primary finding of this impressive study was that a year-long LPG intervention with robust measures to enable LPG stove use was

⊕ This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (<https://creativecommons.org/licenses/by-nc-nd/4.0/>). For commercial usage and reprints, please contact Diane Gern ([dgern@thoracic.org](mailto:dgern@thoracic.org)).

Supported by NHLBI K23HL135349 and NIMHD R01MD013310 (to A.G.L.), and by NIEHS R01ES026991.

Originally Published in Press as DOI: 10.1164/rccm.202012-4353ED on December 24, 2020